Reduces cortisol and stress reactivity and promotes parasympathetic activation to support mood stability and restorative sleep quality
The glucagon receptor agonism in retatrutide introduces additional considerations not seen with GLP-1-only agents
Sitagliptin, a DPP-4 inhibitor, improves myocardial response in coronary artery disease patients
The Wegovy patient leaflet says it acts on receptors in the brain that control appetite, causing people to feel fuller, less hungry and experience less craving for food [3]
"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." December 11, 2025
That's our job as responsible scientists. It also remains unknown whether there will be any new side effects that pop up if people remain on these drugs for 30, 40, or 50-plus years